Thromb Haemost 2005; 93(06): 1027-1035
DOI: 10.1160/TH05-01-0032
Review Article
Schattauer GmbH

Recombinant factor VIIa

An update on its clinical use
Massimo Franchini
1   Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
,
Marco Zaffanello
2   Clinica Pediatrica, Divisione di Ematologia, Università di Verona, Verona, Italy
,
Dino Veneri
3   Dipartimento di Medicina Sperimentale e Clinica, Divisione di Ematologia, Università di Verona, Verona, Italy
› Author Affiliations
Further Information

Publication History

Received 17 January 2005

Accepted after revision 09 March 2005

Publication Date:
11 December 2017 (online)

Zoom Image

Summary

Recombinant activated factor VII (rFVIIa, Novo Seven®) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemos- tatic abnormalities. Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications.